Data Sheet (Cat.No.T10493)

TargetMol

Beclabuvir

Chemical Properties



CAS No. : 958002-33-0

Formula: C36H45N5O5S

Molecular Weight: 659.84

Appearance: no data available

Storage: store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the HCV NS5B RNA-dependent RNA polymerase, inhibiting recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 (IC50 < 28 nM).
Targets(IC50)	HCV Protease
In vitro	2- or 3-drug combinations of beraprevir with pegIFN/RBV and with a range of DAAs (e.g., HCV NS5A inhibitors, NS3 protease inhibitors, and/or nucleoside analog NS5B inhibitors) can show additive or synergistic antiviral activity [2].
In vivo	The combination of Beclabuvir with daclatasvir and asunaprevir achieves very high rates of viral eradication (about 90%) in patients infected with HCV genotype 1, which is the most common genotype worldwide [1].

Solubility Information

Solubility	DMSO: 20 mg/mL (30.31 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.5155 mL	7.5776 mL	15.1552 mL
5 mM	0.3031 mL	1.5155 mL	3.031 mL
10 mM	0.1516 mL	0.7578 mL	1.5155 mL
50 mM	0.0303 mL	0.1516 mL	0.3031 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Gentile I, et al. Beclabuvir for the treatment of hepatitis C. Expert Opin Investig Drugs. 2015;24(8):1111-21
Tatum H, et al. A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. J Viral Hepat. 2015 Aug;22(8):658-64.

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481